Pharmacist-Led Cardiorenal Risk Optimization in a Diabetes Clinic

Key Takeaways

• A retrospective review in a community diabetes clinic found that specialist pharmacist involvement was associated with significant improvements in modifiable cardiorenal risk factors.
• Over a median follow-up of 6 months in 246 patients with type 2 diabetes, HbA1c, blood pressure, and total cholesterol all improved significantly (P < .01).
• The findings support integration of specialist pharmacists into diabetes care to optimize cardiometabolic risk.

The study reflects a real-world clinical setting in which pharmacist involvement was embedded within routine care delivery rather than implemented as a standalone experimental protocol.

The analysis included 246 patients with type 2 diabetes (54% male) treated between February 2023 and October 2023, with a median follow-up duration of 6 months. The evaluation assessed changes in key cardiometabolic parameters commonly linked to diabetes-related complications, providing a clinically relevant measure of risk-factor optimization within the clinic setting.

Significant improvements were observed across multiple modifiable risk factors. Mean HbA1c decreased from 84.5 (18.2) mmol/mol at baseline to 77.6 (20.0) mmol/mol at follow-up. Blood pressure also improved, with mean systolic blood pressure declining from 151.4 (12.8) mmHg to 140.4 (16.3) mmHg and diastolic blood pressure from 87.7 (5.3) mmHg to 82.1 (9.2) mmHg. Total cholesterol decreased from 5.2 (0.9) to 4.9 (1.2). All reported changes were statistically significant (P < .01).

The study did not detail the specific operational structure of pharmacist encounters, such as visit frequency, prescribing authority, or intervention protocols. However, pharmacist involvement was clearly positioned as integrated within routine clinic workflows, contributing to longitudinal management of cardiometabolic risk.

Overall, the findings indicate that incorporation of a specialist pharmacist into a community diabetes clinic was associated with measurable improvements in glycemic control, blood pressure, and lipid levels over a 6-month period. The authors conclude that this model can improve modifiable cardiorenal risk in people with type 2 diabetes, supporting its role in multidisciplinary diabetes care.